問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Tri-Service General Hospital (在職)

Division of Urology

更新時間：2023-09-19

吳勝堂
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

7Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳勝堂

List

11Cases

2021-01-01 - 2029-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2017-06-01 - 2021-01-06

Phase II

Completed
A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

  • Condition/Disease

    Metastatic Castration-Resistant Prostate Cancer

  • Test Drug

    Niraparib

Participate Sites
7Sites

Terminated7Sites

2020-06-01 - 2026-12-31

Phase III

Active
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281)

  • Condition/Disease

    Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency

  • Test Drug

    Capivasertib Abiraterone

Participate Sites
9Sites

Recruiting9Sites

2021-12-20 - 2031-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2014-01-01 - 2024-03-11

Phase III

Asian Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy Naive Subjects with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy

  • Condition/Disease

    Prostate Cancer

  • Test Drug

    enzalutamide

Participate Sites
9Sites

Terminated9Sites

2017-08-01 - 2020-12-31

Phase III

HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer

  • Condition/Disease

    Advanced Prostate Cancer

  • Test Drug

    Relugolix 120 mg

Participate Sites
5Sites

Terminated4Sites

黃書彬
Kaohsiung Municipal Gangshan Hospital

未分科

2020-12-01 - 2022-03-22

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-11-01 - 2022-08-29

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2012-06-01 - 2017-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2010-11-01 - 2011-10-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB